Raymond James & Associates Blueprint Medicines Corp Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

A detailed history of Raymond James & Associates transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Raymond James & Associates holds 16,898 shares of BPMC stock, worth $1.39 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,898
Previous 13,550 24.71%
Holding current value
$1.39 Million
Previous $1.46 Million 6.99%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024
BUY
$84.1 - $120.5 $281,566 - $403,434
3,348 Added 24.71%
16,898 $1.56 Million
Q2 2024

Jul 19, 2024
BUY
$85.18 - $108.78 $359,033 - $458,507
4,215 Added 45.15%
13,550 $1.46 Million
Q1 2024

Apr 22, 2024
SELL
$73.17 - $99.79 $99,291 - $135,415
-1,357 Reduced 12.69%
9,335 $885,000
Q4 2023

Jan 16, 2024
SELL
$43.96 - $92.84 $384,869 - $812,814
-8,755 Reduced 45.02%
10,692 $986,000
Q3 2023

Oct 24, 2023
SELL
$46.9 - $66.0 $482,507 - $679,008
-10,288 Reduced 34.6%
19,447 $976,000
Q2 2023

Jul 25, 2023
BUY
$42.2 - $66.37 $617,765 - $971,590
14,639 Added 96.97%
29,735 $1.88 Million
Q1 2023

Apr 14, 2023
BUY
$37.97 - $50.0 $31,097 - $40,950
819 Added 5.74%
15,096 $679,000
Q4 2022

Feb 08, 2023
SELL
$41.06 - $66.48 $704,425 - $1.14 Million
-17,156 Reduced 54.58%
14,277 $625,000
Q3 2022

Oct 25, 2022
BUY
$49.93 - $77.7 $127,371 - $198,212
2,551 Added 8.83%
31,433 $2.07 Million
Q2 2022

Aug 12, 2022
SELL
$45.23 - $70.15 $121,352 - $188,212
-2,683 Reduced 8.5%
28,882 $1.46 Million
Q1 2022

May 11, 2022
BUY
$54.1 - $110.08 $267,524 - $544,345
4,945 Added 18.58%
31,565 $2.02 Million
Q4 2021

Feb 08, 2022
BUY
$94.25 - $115.99 $614,510 - $756,254
6,520 Added 32.44%
26,620 $2.85 Million
Q3 2021

Nov 02, 2021
BUY
$80.98 - $109.47 $169,005 - $228,463
2,087 Added 11.59%
20,100 $2.07 Million
Q2 2021

Aug 11, 2021
SELL
$82.78 - $101.0 $19,370 - $23,634
-234 Reduced 1.28%
18,013 $1.58 Million
Q1 2021

May 14, 2021
SELL
$90.71 - $108.28 $1.45 Million - $1.73 Million
-15,944 Reduced 46.63%
18,247 $1.77 Million
Q4 2020

Feb 12, 2021
SELL
$92.08 - $124.48 $348,706 - $471,405
-3,787 Reduced 9.97%
34,191 $3.84 Million
Q3 2020

Nov 04, 2020
BUY
$66.45 - $92.7 $400,361 - $558,517
6,025 Added 18.86%
37,978 $3.52 Million
Q2 2020

Jul 28, 2020
BUY
$57.09 - $79.27 $136,502 - $189,534
2,391 Added 8.09%
31,953 $2.49 Million
Q1 2020

Apr 21, 2020
BUY
$48.11 - $82.22 $252,481 - $431,490
5,248 Added 21.58%
29,562 $1.73 Million
Q4 2019

Feb 12, 2020
BUY
$66.73 - $82.59 $1.04 Million - $1.28 Million
15,546 Added 177.3%
24,314 $1.95 Million
Q3 2019

Nov 07, 2019
BUY
$72.9 - $101.41 $54,018 - $75,144
741 Added 9.23%
8,768 $644,000
Q2 2019

Aug 06, 2019
SELL
$73.54 - $97.8 $147,227 - $195,795
-2,002 Reduced 19.96%
8,027 $757,000
Q1 2019

May 06, 2019
SELL
$48.7 - $86.6 $31,070 - $55,250
-638 Reduced 5.98%
10,029 $803,000
Q4 2018

Feb 11, 2019
SELL
$45.57 - $74.26 $3,144 - $5,123
-69 Reduced 0.64%
10,667 $575,000
Q3 2018

Nov 14, 2018
BUY
$58.91 - $78.32 $632,457 - $840,843
10,736 New
10,736 $838,000
Q2 2018

Aug 14, 2018
SELL
$60.96 - $101.18 $155,813 - $258,616
-2,556 Closed
0 $0
Q1 2018

May 14, 2018
SELL
$73.28 - $102.95 $32,829 - $46,121
-448 Reduced 14.91%
2,556 $234,000
Q4 2017

Feb 14, 2018
SELL
$62.91 - $88.32 $8,367 - $11,746
-133 Reduced 4.24%
3,004 $227,000
Q3 2017

Nov 13, 2017
BUY
$42.37 - $69.67 $132,914 - $218,554
3,137
3,137 $219,000

Others Institutions Holding BPMC

# of Institutions
380
Shares Held
61.5M
Call Options Held
1.6M
Put Options Held
1.41M
View Full List

About Blueprint Medicines Corp

BPMC Quotes by TradingView
  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $4.93B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email